Jeff Yass’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.89M Buy
72,500
+67,100
+1,243% +$4.07M ﹤0.01% 4664
2026
Q1
$299K Sell
5,400
-299,100
-98% -$16.1M ﹤0.01% 10860
2025
Q4
$14.8M Buy
304,500
+92,800
+44% +$3.62M ﹤0.01% 2557
2025
Q3
$6.48M Buy
211,700
+114,600
+118% +$2.63M ﹤0.01% 3682
2025
Q2
$2.16M Sell
97,100
-40,000
-29% -$837K ﹤0.01% 5635
2025
Q1
$2.55M Sell
137,100
-216,200
-61% -$3.61M ﹤0.01% 4999
2024
Q4
$4.68M Buy
353,300
+241,400
+216% +$5.85M ﹤0.01% 3698
2024
Q3
$3.75M Buy
+111,900
New +$3.82M ﹤0.01% 4127
2023
Q2
Sell
-31,200
Closed -$679K 11992
2023
Q1
$679K Sell
31,200
-2,800
-8% -$68K ﹤0.01% 7803
2022
Q4
$1.05M Buy
+34,000
New +$960K ﹤0.01% 6070
2022
Q3
Sell
-10,100
Closed -$205K 13101
2022
Q2
$205K Buy
+10,100
New +$224K ﹤0.01% 10562
2021
Q4
Sell
-10,100
Closed -$274K 13053
2021
Q3
$274K Sell
10,100
-14,300
-59% -$363K ﹤0.01% 10792
2021
Q2
$633K Sell
24,400
-104,100
-81% -$2.5M ﹤0.01% 8988
2021
Q1
$2.77M Buy
+128,500
New +$3.24M ﹤0.01% 5146
2020
Q4
Sell
-10,200
Closed -$150K 10967
2020
Q3
$150K Sell
10,200
-1,900
-16% -$34.3K ﹤0.01% 9681
2020
Q2
$270K Sell
12,100
-30,000
-71% -$548K ﹤0.01% 8534
2020
Q1
$595K Sell
42,100
-55,500
-57% -$842K ﹤0.01% 6545
2019
Q4
$1.59M Sell
97,600
-126,600
-56% -$2.99M ﹤0.01% 4697
2019
Q3
$7.84M Buy
224,200
+116,700
+109% +$5.55M ﹤0.01% 2226
2019
Q2
$6.07M Buy
107,500
+34,500
+47% +$2.48M ﹤0.01% 2463
2019
Q1
$5.33M Sell
73,000
-12,600
-15% -$870K ﹤0.01% 2367
2018
Q4
$5.46M Buy
85,600
+9,500
+12% +$706K ﹤0.01% 2183
2018
Q3
$7.59M Buy
76,100
+2,600
+4% +$216K ﹤0.01% 2200
2018
Q2
$5.22M Sell
73,500
-310,200
-81% -$26M ﹤0.01% 2654
2018
Q1
$39.9M Buy
383,700
+246,800
+180% +$27.8M 0.01% 773
2017
Q4
$13.8M Buy
+136,900
New +$10.1M ﹤0.01% 1550

Other funds holding ANAB

Jeff Yass's ANAB Position: Q2 2026 in Review

Jeff Yass sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 26,577 shares — an estimated $1.61M sold.

Jeff Yass first reported a position in ANAB in Q4 2017 and held it in 30 quarters. The position peaked at $8.88M in Q1 2018. 211 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Jeff Yass reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 26,577 AnaptysBio shares in Q2 2026, an estimated $1.61M.
  • Jeff Yass first reported a position in AnaptysBio in Q4 2017 and held it in 30 quarters.
  • Jeff Yass's AnaptysBio position peaked at $8.88M in Q1 2018.
  • 211 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.